POSSIBILITIES TO USE A FIXED COMBINATION OF PIRACETAM AND CINNARIZINE IN NEUROLOGICAL PRACTICE

The article discusses  the  possibility of using the  complex drug Phezam, containing 400  mg of Piracetam and 25  mg of Cinnarizine in neurological practice. The advantage of a combination of nootropic and vasoactive substances is due to a balanced and diversified influence on the different links of pathogenesis  diseases. Piracetam targets the turnover of cell membranes, neurotransmission, has a neuroprotective effect, influences the neuroplasticity, the energy exchange in the cage and the vascular mechanisms (blood cells, cardiovascular wall and coagulation). The second component of the drug Cinnarizine has vasodilatating properties, suppresses the activity of the labyrinth and improves flow blood properties. When discussing the drug-induced parkinsonism, the opposite  effects  of the drug components on the dopaminergic system are described. The Phezam has shown its efficacy in the preventive treatment of migraines (reducing of frequency and intensity of seizures). In patients with chronic brain ischemia Phezam improved a neurological status, cognitive functions, blood flow indicators, and quality of life. The positive effects of Phezam during the recovery period of ischaemic stroke with speech and moderate cognitive disorders are reported. The characteristics of the metering regime are the possibility to use low-and high-dosage therapy. The drug showed good tolerability and economic advantages over the use of active substances separately.

1. Fassoulaki A, Kostopanagiotou G, Kaniaris P, Varonos DD. Piracetam attenuates the changes in the surface potential of the phosphatidylcholine monolayer produced by alcohols. Acta Anaesthesiol Belg, 1985, 36: 47-51.

2. Mingeot-Leclercq MP, Lins L, Bensliman M, Thomas A, Van Bambeke F, Peuvot J et al. Piracetam inhibits the lipid-destabilising effect of the amyloid peptide Abeta C-terminal fragment. Biochim Biophys Acta, 2003, 1609(1): 28-38.

3. Müller WE, Koch S, Scheuer K, Rostock A, Bartsch R. Effects of piracetam on membrane fluidity in the aged mouse, rat and human brain. Biochem Pharmacol, 1997, 53: 135-140.

4. Scheuer K, Stoll S, Paschke U, Weigel R, Müller WE. N-methyl-D-aspartate receptor density and membrane fluidity as possible determinants of the decline of passive avoidance performance in aging. Pharmacol Biochem Behav, 1995, 50: 65-70.

5. Müller WE. Age related quantitative and qualitative receptor changes and pharmacological reactivity. In: Racagni G, Mendlewicz J, Eds. Treatment of age-related cognitive dysfunction: Pharmacological and clinical evaluation. Int Acad Biomed Drug Res. Basel: Karger 1992, 2: 35-40.

6. Pilch H, Müller WE. Piracetam elevates muscarinic cholinergic receptor density in the frontal cortex of aged but not of young mice. Psychopharmacology, 1988, 94: 74-78.

7. Stoll L, Schubert T, Müller WE. Age-related deficits of central muscarinic cholinergic receptor function in the mouse: Partial restoration by chronic piracetam treatment. Neurobiol Aging, 1992, 13: 39-44.

8. Wurtman RJ, Magic SG, Reinstein DK. Piracetam decreases hippocampal acetylcholine levels in rats. Life Sci, 1981, 28: 1091-1093.

9. Valzelli L, Bernasconi S, Sala A. Piracetam activity may differ according to the age of the recipient mouse. Int Pharmacopsychiatry, 1980, 15: 150-156.

10. Olpe H-R, Steinmann MW. The activating action of vincamine, piracetam and hydergine on the activity of the noradrenergic neurons of the locus coeruleus. Behav Neural Biol, 1981, 33: 249-251.

11. Cohen SA, Müller WE. Effects of piracetam on N-methyl-D-aspartate receptor properties in the aged mouse brain. Pharmacology, 1993, 47: 217-222.

12. Ahmed A, Oswald R. Piracetam Defines a New Binding Site for Allosteric Modulators of α amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors. Journal of Medicinal Chemistry, 2010, 53(5): 2197-2203.

13. Paula-Barbosa MM, Brandao F, Pinho MC, Andrade JP, Madeira MD, Cadete-Leite A. The effects of piracetam on lipofuscin of the rat cerebellar and hippocampal neurons after long-term alcohol treatment and withdrawal: A quantitative study. Alcohol Clin Exp Res, 1991, 15: 834-838.

14. Xerri C, Zennou-Azogui Y. Influence of the postlesion environment and chronic piracetam treatment on the organization of the somatotopic map in the rat primary somatosensory cortex after focal cortical injury. Neuroscience, 2003, 118: 161-177.

15. Winblad B. Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev, 2005, 11(2): 169-182.

16. Brandao F, Cadete-Leite A, Andrade JP, Madeira MD, Paula-Barbosa MM. Piracetam promotes mossy fiber synaptic reorganization in rats withdrawn from alcohol. Alcohol, 1996, 13: 239-249.

17. Brandao F, Paula-Barbosa MM, Cadete-Leite A. Piracetam impedes hippocampal neuronal loss during withdrawal after chronic alcohol intake. Alcohol, 1995, 12: 279-288.

18. Grau M, Montero JL, Balasch J. Effect of Piracetam on electrocorticogram and local cerebral glucose utilization in the rat. General pharmacology, 1987, 18(2): 205-211.

19. Nickolson VJ, Wolthuis OL. Effect of the acquisition-enhancing drug piracetam on rat cerebral energy metabolism. Comparison with naftidrofuryl and methamphetamine. Biochemical pharmacology, 1976, 25(20): 2241-2244.

20. Tacconi, MT, Wurtman RJ. Piracetam: physiological disposition and mechanism of action. Advances in neurology, 1986, 43: 675-685.

21. Nalbandian RM, Henry RL, Burek CL, Diglio СА, Goldman AI; Taylor GW et al. Diminished adherence of sickle erythrocytes to cultured vascular endothelium by piracetam. Am J Hematol, 1983, 15: 147-151.

22. Reuse-Blom S. Microcirculation of the pial vessels in the rabbit. Acta Cardiol, 1979, 34: 35-36.

23. Moriau M, Crasborn L, Lavenne-Pardonge E, Von Frenckell R, Col-Debeys C. Platelet anti-aggregant and rheological properties of piracetam. Arzneimittelforschung, 1993, 43: 110-118.

24. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature, 1976, 263: 663-665.

25. Moncada S, Herman AG, Higgs EA, Vane JR. Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res, 1977, 11: 323-344.

26. Moncada S, Higgs EA, Vane JR. Human arterial and venous tissues generate prostacyclin (prostaglandin PgI2), a potent inhibitor of platelet aggregation. Lancet, 1977, 1: 18-20.

27. Schror K, Link HB, Rosen R, Klaus W, Rosen P. Prostacyclin-induced coronary vasodilation. Interactions with adenosine, cyclic AMP and energy charge in the rat heart in vitro. Eur J Pharmacol, 1980, 64: 341-348.

28. Herrschaft H. The effect of piracetam on global and regional cerebral blood flow in acute cerebral ischemia of man. Med Klin, 1978, 73: 195-202.

29. Sato M, Heiss WD. Effect of piracetam on cerebral blood flow and somatosensory evoked potential during normotension and hypotensive ischemia in cats. Arzneimittelforschung, 1985, 35: 790-792.

30. Poignet H, Beaughard M, Lecoin G, Massingham R. Functional, Behavioral, and Histological Changes Induced by Transient Global Cerebral Ischemia in Rats: Effects of Cinnarizine and Flunarizine. Journal of Cerebral Blood Flow & Metabolism, 1989, 9(5): 646-654.

31. Deka CVR. Role of Cinnarizine in Peripheral Vertigo. Vertigo Viewpoint, 2006, 4(1): 2-4.

32. Towse G. Cinnarizine a labyrinthine sedative. The Journal of laryngology and otology, 1980, 94(9): 1009-1015.

33. Miguel R, Correia AS, Bugalho P. Iatrogenic parkinsonism: the role of flunarizine and cinnarizine. J Parkinsons Dis, 2014, 4(4): 645-649.

34. Benvenuti F, Baroni A, Bandinelli S, Ferrucci L, Corradetti R, Pantaleo T. Flunarizine-induced parkinsonism in the elderly. J Clin Pharmacol, 1988, 28: 600-608.

35. Garcıa-Ruiz PJ, Garcıa de Yebenes J, JimenezJimenez FJ, Vazquez A, Garcıa Urra D, Morales B. Parkinsonism associated with calcium channel blockers: A prospective follow-up study. Clin Neuropharmacol, 1992, 15: 19-26.

36. Jimenez-Jimenez FJ, Ortı-Pareja M, AyusoPeralta L, Gasalla T, Cabrera-Valdivia F, Vaquero A et al. Drug-induced parkinsonism in a movement disorders unit: A four-year survey. Parkinsonism Relat Disord, 1996, 2: 145-149.

37. Negrotti A, Calzetti S. A long-term follow-up study of cinnarizineand flunarizine-induced parkinsonism. Mov Disord, 1997, 12: 107-110.

38. Garcıa-Ruiz PJ, Jimenez-Jimenez F, Garcıa de Yebenes J. Calcium channel blocker-induced parkinsonism: Clinical features and comparisons with Parkinson’s disease. Parkinsonism Relat Disord, 1998, 4: 211-214.

39. Terland O, Flatmark T. Drug-induced parkinsonism: Cinnarizine and flunarizine are potent uncouplers of the vacuolar H+-ATPase in catecholamine storage vesicles. Neuropharmacology, 1999, 38(6): 879-882.

40. Serrano A, Menendez J, Casarejos M, Solano R, Gallego E, Sanchez M et al. Effects of cinnarizine, a calcium antagonist that produces human parkinsonism, in parkin knock out mice. Neuropharmacology, 2005, 49(2): 208-219.

41. Fabiani G, Pastro PC, Froehner C. Parkinsonism and other movement disorders in outpatients in chronic use of cinnarizine and flunarizine Arquivos de neuro-psiquiatria, 2004, 62(3B): 784-788.

42. Budygin EA, Gainetdinov RR, Titov DA, Kovalev GI. The effect of a low dose of piracetam on the activity of the dopaminergic system in the rat striatum. Eksp Klin Farmakol, 1996, 59(2): 6-8.

43. Zaitone SA, Abo-Elmatty DM, Elshazly SM. Piracetam and vinpocetine ameliorate rotenone-induced Parkinsonism in rats. Indian J Pharmacol, 2012, 44(6): 774-779.

44. Kaniecki R, Lucas S. Treatment of primary headache: preventive treatment of migraine. In: Standarts of care for headache diagnosis and treatment. Chicago (IL): National Headache Foundation, 2004: 40-52.

45. Табеева Г.Р. Головная боль: Руководство для врачей. М.: ГЭОТАР-Медиа, 2014, 288 с.

46. Togha M, Malamiri RA, Rashidi-Ranjbar N, Asa S, Mahvelati F, Ashrafi MR. Efficacy and safety of cinnarizine in the prophylaxis of migraine headaches in children: an open, randomized comparative trial with propranolol. Acta Neurol Belg, 2012, 112: 51-55.

47. Togha M, Rahmat Jirde M, Nilavari K, Ashrafian H, Razeghi S, Kohan L. Cinnarizine in refractory migraine prophylaxis: efficacy and tolerability. A comparison with sodium valproate. J Headache Pain, 2008, 9: 77-82.

48. Тарасова С.В., Соколова А.Ю., Тумелевич Б.Ч., Амелин А.В., Скоромец А.А. Сравнительная эффективность Фезама и циннаризина у пациентов с мигренью. РМЖ, 2006, 14(22): 1-4.

49. Кабанов А.А., Бойко А.Н., Еськина Т.А., Шелякина Л.А., Щукин А.И., Батышева Т.Т. и др. Применение Фезама у больных с хроническими формами нарушения мозгового кровообращения. Неврологический журнал, 2004, 9(2): 65-67.

50. Fazekas F, Offenbacher H, Fuchs S, Schmidt R, Niederkorn K, Horner S et al. Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis. Neurology, 1988, 38: 1822-1825.

51. Гусев Е.И., Бойко А.Н., Кольяк Е.В., Каралкин А.В., Камчатнов П.Р., Мартынов М.Ю. Вклад нарушений микроциркуляции в формирование клинической картины рассеянного склероза у больных старше 45 лет и возможные направления коррекции сосудистой патологии. Журнал неврологии и психиатрии им. С.С. Корсакова, 2008, 108(5): 25-31.

52. Щукин И.А., Лебедева А.В., Бурд С.Г., Шихкеримов Р.К., Исмаилов А.М., Болотов А.В. и др. Хронические цереброваскулярные заболевания: вопросы диагностики и лечения. Consilium Medicum, 2016, 18(2): 85-94.

53. Арабханова М.А., Пышкина Л.И., Кабанов А.А., Колесникова Т.И., Ясаманова А.Н., Мартынов М.Ю. и др. Фезам в комплексном лечении нарушений мозгового кровообращения. Журнал неврологии и психиатрии им. С.С. Корсакова, 2008, 108(2): 24-26.

54. Кабанов А.А., Бойко А.Н., Еськина Т.А., Шелякина Л.А., Щукин И.А., Батышева Т.Т. и др. Фармакоэкономические аспекты лечения больных с хроническими формами нарушения мозгового кровообращения фезамом, пирацетамом и циннаризином. Трудный пациент, 2004, 4: 12-17.